cilostazol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 644 | 73963-72-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 7.73 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 15, 1999 | FDA | OTSUKA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 78.94 | 16.54 | 36 | 4081 | 23857 | 63461048 |
| Ventricular fibrillation | 45.97 | 16.54 | 20 | 4097 | 11847 | 63473058 |
| Acinetobacter test positive | 36.04 | 16.54 | 6 | 4111 | 78 | 63484827 |
| Nikolsky's sign | 34.70 | 16.54 | 6 | 4111 | 99 | 63484806 |
| Gastrointestinal haemorrhage | 31.11 | 16.54 | 32 | 4085 | 81144 | 63403761 |
| Urticaria vesiculosa | 29.03 | 16.54 | 4 | 4113 | 12 | 63484893 |
| Cardiac failure | 28.62 | 16.54 | 32 | 4085 | 89110 | 63395795 |
| Pyogenic granuloma | 28.14 | 16.54 | 6 | 4111 | 308 | 63484597 |
| Cerebral haemorrhage | 25.87 | 16.54 | 19 | 4098 | 30710 | 63454195 |
| Anaemia | 24.74 | 16.54 | 57 | 4060 | 293373 | 63191532 |
| Subarachnoid haemorrhage | 22.29 | 16.54 | 13 | 4104 | 14270 | 63470635 |
| Parotid gland enlargement | 22.14 | 16.54 | 6 | 4111 | 852 | 63484053 |
| Cardiac failure congestive | 21.21 | 16.54 | 28 | 4089 | 92405 | 63392500 |
| Acute leukaemia | 20.49 | 16.54 | 6 | 4111 | 1128 | 63483777 |
| Torsade de pointes | 20.43 | 16.54 | 12 | 4105 | 13339 | 63471566 |
| Myocardial infarction | 19.52 | 16.54 | 28 | 4089 | 99865 | 63385040 |
| Upper respiratory tract inflammation | 19.46 | 16.54 | 7 | 4110 | 2516 | 63482389 |
| Peripheral arterial occlusive disease | 19.32 | 16.54 | 8 | 4109 | 4193 | 63480712 |
| Shock | 18.61 | 16.54 | 14 | 4103 | 23449 | 63461456 |
| Colonic haematoma | 18.16 | 16.54 | 3 | 4114 | 37 | 63484868 |
| Enterobacter test positive | 18.00 | 16.54 | 4 | 4113 | 249 | 63484656 |
| Kounis syndrome | 17.99 | 16.54 | 6 | 4111 | 1724 | 63483181 |
| Infectious mononucleosis | 17.32 | 16.54 | 6 | 4111 | 1933 | 63482972 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 72.73 | 16.09 | 52 | 6621 | 27403 | 34922855 |
| Interstitial lung disease | 43.81 | 16.09 | 58 | 6615 | 65224 | 34885034 |
| Hepatic function abnormal | 38.73 | 16.09 | 45 | 6628 | 44318 | 34905940 |
| Cerebral hyperperfusion syndrome | 34.57 | 16.09 | 7 | 6666 | 90 | 34950168 |
| Sprue-like enteropathy | 31.79 | 16.09 | 9 | 6664 | 504 | 34949754 |
| Cardiac vein perforation | 28.87 | 16.09 | 5 | 6668 | 25 | 34950233 |
| Renal impairment | 27.89 | 16.09 | 58 | 6615 | 94455 | 34855803 |
| Lacunar infarction | 27.81 | 16.09 | 13 | 6660 | 3077 | 34947181 |
| Peripheral arterial occlusive disease | 27.67 | 16.09 | 16 | 6657 | 5858 | 34944400 |
| Therapeutic drug monitoring analysis incorrectly performed | 26.08 | 16.09 | 7 | 6666 | 321 | 34949937 |
| Decreased appetite | 24.91 | 16.09 | 79 | 6594 | 166313 | 34783945 |
| Contrast encephalopathy | 24.16 | 16.09 | 5 | 6668 | 72 | 34950186 |
| Gastrointestinal haemorrhage | 23.46 | 16.09 | 52 | 6621 | 88425 | 34861833 |
| Intermittent claudication | 21.73 | 16.09 | 10 | 6663 | 2284 | 34947974 |
| Thrombosis in device | 21.02 | 16.09 | 11 | 6662 | 3314 | 34946944 |
| Cerebral haemorrhage | 20.33 | 16.09 | 29 | 6644 | 34908 | 34915350 |
| Hemiplegia | 20.29 | 16.09 | 14 | 6659 | 6958 | 34943300 |
| Foot amputation | 20.27 | 16.09 | 7 | 6666 | 754 | 34949504 |
| Haemobilia | 20.21 | 16.09 | 6 | 6667 | 398 | 34949860 |
| Diarrhoea | 20.09 | 16.09 | 135 | 6538 | 389777 | 34560481 |
| Basal ganglia haematoma | 19.93 | 16.09 | 4 | 6669 | 49 | 34950209 |
| Haematochezia | 19.24 | 16.09 | 33 | 6640 | 46501 | 34903757 |
| Renal haemorrhage | 19.16 | 16.09 | 8 | 6665 | 1449 | 34948809 |
| Altered state of consciousness | 17.95 | 16.09 | 22 | 6651 | 22871 | 34927387 |
| Peripheral artery occlusion | 17.91 | 16.09 | 8 | 6665 | 1704 | 34948554 |
| Toxicity to various agents | 17.80 | 16.09 | 8 | 6665 | 200354 | 34749904 |
| Peripheral artery restenosis | 17.67 | 16.09 | 3 | 6670 | 13 | 34950245 |
| Vascular stent thrombosis | 16.56 | 16.09 | 9 | 6664 | 2926 | 34947332 |
| Gastric cancer | 16.53 | 16.09 | 12 | 6661 | 6457 | 34943801 |
| Chronic pigmented purpura | 16.51 | 16.09 | 4 | 6669 | 121 | 34950137 |
| Thrombotic cerebral infarction | 16.24 | 16.09 | 5 | 6668 | 375 | 34949883 |
| Labelled drug-drug interaction medication error | 16.22 | 16.09 | 17 | 6656 | 14922 | 34935336 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 144.16 | 14.18 | 84 | 10366 | 45592 | 79688346 |
| Interstitial lung disease | 58.63 | 14.18 | 73 | 10377 | 112527 | 79621411 |
| Gastrointestinal haemorrhage | 51.63 | 14.18 | 79 | 10371 | 147640 | 79586298 |
| Hepatic function abnormal | 49.06 | 14.18 | 54 | 10396 | 73053 | 79660885 |
| Peripheral arterial occlusive disease | 48.41 | 14.18 | 23 | 10427 | 8235 | 79725703 |
| Cerebral haemorrhage | 41.13 | 14.18 | 44 | 10406 | 57629 | 79676309 |
| Renal impairment | 36.16 | 14.18 | 70 | 10380 | 157713 | 79576225 |
| Cardiac failure | 35.86 | 14.18 | 69 | 10381 | 154773 | 79579165 |
| Cerebral hyperperfusion syndrome | 35.04 | 14.18 | 7 | 10443 | 125 | 79733813 |
| Anaemia | 33.59 | 14.18 | 131 | 10319 | 444884 | 79289054 |
| Lacunar infarction | 33.12 | 14.18 | 16 | 10434 | 5941 | 79727997 |
| Ventricular fibrillation | 31.36 | 14.18 | 29 | 10421 | 31897 | 79702041 |
| Peripheral artery occlusion | 31.28 | 14.18 | 12 | 10438 | 2545 | 79731393 |
| Cardiac vein perforation | 30.75 | 14.18 | 5 | 10445 | 25 | 79733913 |
| Subarachnoid haemorrhage | 29.58 | 14.18 | 25 | 10425 | 24440 | 79709498 |
| Pneumonia aspiration | 29.50 | 14.18 | 40 | 10410 | 66927 | 79667011 |
| Joint swelling | 27.28 | 14.18 | 3 | 10447 | 288643 | 79445295 |
| Altered state of consciousness | 27.04 | 14.18 | 31 | 10419 | 43791 | 79690147 |
| Contrast encephalopathy | 27.00 | 14.18 | 6 | 10444 | 182 | 79733756 |
| Decreased appetite | 26.79 | 14.18 | 102 | 10348 | 342316 | 79391622 |
| Upper gastrointestinal haemorrhage | 26.77 | 14.18 | 30 | 10420 | 41350 | 79692588 |
| Peripheral artery restenosis | 26.48 | 14.18 | 4 | 10446 | 11 | 79733927 |
| Urticaria vesiculosa | 26.22 | 14.18 | 4 | 10446 | 12 | 79733926 |
| Cardiac failure congestive | 25.38 | 14.18 | 57 | 10393 | 142345 | 79591593 |
| Foot amputation | 25.28 | 14.18 | 8 | 10442 | 960 | 79732978 |
| Nikolsky's sign | 25.13 | 14.18 | 6 | 10444 | 251 | 79733687 |
| Acinetobacter test positive | 24.99 | 14.18 | 6 | 10444 | 257 | 79733681 |
| Haemorrhage subcutaneous | 24.00 | 14.18 | 12 | 10438 | 4797 | 79729141 |
| Blood pressure decreased | 23.84 | 14.18 | 45 | 10405 | 99421 | 79634517 |
| Melaena | 23.30 | 14.18 | 34 | 10416 | 60856 | 79673082 |
| Therapeutic drug monitoring analysis incorrectly performed | 23.28 | 14.18 | 7 | 10443 | 709 | 79733229 |
| Drug ineffective | 23.28 | 14.18 | 69 | 10381 | 1080844 | 78653094 |
| Sprue-like enteropathy | 22.86 | 14.18 | 8 | 10442 | 1310 | 79732628 |
| Aortic dissection | 22.56 | 14.18 | 11 | 10439 | 4164 | 79729774 |
| Hemiplegia | 21.71 | 14.18 | 17 | 10433 | 14922 | 79719016 |
| Labelled drug-drug interaction medication error | 21.32 | 14.18 | 22 | 10428 | 27628 | 79706310 |
| Haematoma | 21.22 | 14.18 | 30 | 10420 | 52165 | 79681773 |
| Pyogenic granuloma | 21.00 | 14.18 | 6 | 10444 | 509 | 79733429 |
| Parotid gland enlargement | 20.99 | 14.18 | 7 | 10443 | 991 | 79732947 |
| Pneumonia | 20.95 | 14.18 | 153 | 10297 | 660093 | 79073845 |
| Haemobilia | 20.85 | 14.18 | 6 | 10444 | 522 | 79733416 |
| Vascular stent thrombosis | 20.73 | 14.18 | 10 | 10440 | 3700 | 79730238 |
| Basal ganglia haematoma | 20.68 | 14.18 | 4 | 10446 | 60 | 79733878 |
| Gastric cancer | 20.26 | 14.18 | 14 | 10436 | 10165 | 79723773 |
| Drug intolerance | 19.98 | 14.18 | 5 | 10445 | 264114 | 79469824 |
| Thrombosis in device | 19.81 | 14.18 | 11 | 10439 | 5431 | 79728507 |
| Subdural haematoma | 18.99 | 14.18 | 22 | 10428 | 31412 | 79702526 |
| Peripheral ischaemia | 18.80 | 14.18 | 13 | 10437 | 9444 | 79724494 |
| Renal haemorrhage | 18.68 | 14.18 | 8 | 10442 | 2248 | 79731690 |
| Acute myocardial infarction | 18.64 | 14.18 | 35 | 10415 | 77001 | 79656937 |
| Intermittent claudication | 18.32 | 14.18 | 9 | 10441 | 3462 | 79730476 |
| Muscle haemorrhage | 18.32 | 14.18 | 11 | 10439 | 6289 | 79727649 |
| Shock | 17.66 | 14.18 | 25 | 10425 | 43523 | 79690415 |
| Liver disorder | 17.64 | 14.18 | 33 | 10417 | 72384 | 79661554 |
| Fatigue | 17.45 | 14.18 | 63 | 10387 | 929664 | 78804274 |
| Drug interaction | 17.26 | 14.18 | 103 | 10347 | 415080 | 79318858 |
| Atrial fibrillation | 17.17 | 14.18 | 61 | 10389 | 197825 | 79536113 |
| Toxicity to various agents | 17.12 | 14.18 | 18 | 10432 | 421522 | 79312416 |
| Gangrene | 17.07 | 14.18 | 12 | 10438 | 8952 | 79724986 |
| Gastric ulcer haemorrhage | 16.99 | 14.18 | 12 | 10438 | 9015 | 79724923 |
| Blood alkaline phosphatase increased | 16.76 | 14.18 | 30 | 10420 | 63634 | 79670304 |
| Haematochezia | 16.64 | 14.18 | 36 | 10414 | 87609 | 79646329 |
| Putamen haemorrhage | 16.58 | 14.18 | 5 | 10445 | 512 | 79733426 |
| Loss of consciousness | 16.53 | 14.18 | 54 | 10396 | 167889 | 79566049 |
| Alopecia | 16.34 | 14.18 | 5 | 10445 | 231350 | 79502588 |
| Sinus node dysfunction | 16.29 | 14.18 | 11 | 10439 | 7690 | 79726248 |
| Angina unstable | 16.20 | 14.18 | 15 | 10435 | 16512 | 79717426 |
| Thrombotic cerebral infarction | 16.08 | 14.18 | 5 | 10445 | 567 | 79733371 |
| Chronic pigmented purpura | 15.38 | 14.18 | 4 | 10446 | 238 | 79733700 |
| Arteriovenous fistula | 15.31 | 14.18 | 6 | 10444 | 1348 | 79732590 |
| Pemphigoid | 15.21 | 14.18 | 14 | 10436 | 15301 | 79718637 |
| Rhabdomyolysis | 14.83 | 14.18 | 38 | 10412 | 103093 | 79630845 |
| Post procedural haemorrhage | 14.50 | 14.18 | 13 | 10437 | 13731 | 79720207 |
| Cardiac tamponade | 14.45 | 14.18 | 11 | 10439 | 9265 | 79724673 |
| Upper respiratory tract inflammation | 14.27 | 14.18 | 8 | 10442 | 4027 | 79729911 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B01AC23 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin |
| FDA MoA | N0000175086 | Phosphodiesterase 3 Inhibitors |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D001993 | Bronchodilator Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D005343 | Fibrinolytic Agents |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D018696 | Neuroprotective Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D058987 | Phosphodiesterase 3 Inhibitors |
| MeSH PA | D010726 | Phosphodiesterase Inhibitors |
| MeSH PA | D010975 | Platelet Aggregation Inhibitors |
| MeSH PA | D020011 | Protective Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| FDA EPC | N0000175598 | Phosphodiesterase 3 Inhibitor |
| CHEBI has role | CHEBI:35523 | bronchodilator |
| CHEBI has role | CHEBI:35620 | vasodilator agents |
| CHEBI has role | CHEBI:48676 | fibrin modulating agent |
| CHEBI has role | CHEBI:50249 | anticoagulants |
| CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
| CHEBI has role | CHEBI:50568 | 3,5-cyclic nucleoside monophosphate phosphodiesterase inhibitors |
| CHEBI has role | CHEBI:63726 | neuroprotective agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Intermittent claudication | indication | 63491006 | DOID:3669 |
| Chronic heart failure | contraindication | 48447003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Enzyme | INHIBITOR | IC50 | 6.70 | IUPHAR | CHEMBL | |||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5 | DRUG MATRIX | |||||
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Enzyme | INHIBITOR | IC50 | 6.42 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4021153 | VUID |
| N0000148605 | NUI |
| D01896 | KEGG_DRUG |
| 21107 | RXNORM |
| 4021153 | VANDF |
| C0055729 | UMLSCUI |
| CHEBI:31401 | CHEBI |
| CHEMBL799 | ChEMBL_ID |
| DB01166 | DRUGBANK_ID |
| D000077407 | MESH_DESCRIPTOR_UI |
| 2754 | PUBCHEM_CID |
| 7148 | IUPHAR_LIGAND_ID |
| 5680 | INN_ID |
| N7Z035406B | UNII |
| 14036 | MMSL |
| 60734 | MMSL |
| 7889 | MMSL |
| d04382 | MMSL |
| 007339 | NDDF |
| 116087001 | SNOMEDCT_US |
| 395239000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0028 | TABLET | 50 mg | ORAL | ANDA | 27 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0028 | TABLET | 50 mg | ORAL | ANDA | 27 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0044 | TABLET | 100 mg | ORAL | ANDA | 27 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0044 | TABLET | 100 mg | ORAL | ANDA | 27 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2064 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2064 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2064 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2064 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2065 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2065 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2065 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2065 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0123 | TABLET | 50 mg | ORAL | ANDA | 29 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0223 | TABLET | 100 mg | ORAL | ANDA | 29 sections |
| CILOSTAZOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-285 | TABLET | 100 mg | ORAL | ANDA | 22 sections |
| cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-453 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5329 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5329 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-176 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-177 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5411 | TABLET | 100 mg | ORAL | ANDA | 16 sections |
| cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-2521 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-2522 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8795 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8795 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8795 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8796 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8796 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8796 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
| Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-3844 | TABLET | 50 mg | ORAL | ANDA | 26 sections |